TAXUS IV Data Suggest Advantage For Paclitaxel-Eluting Stent In Diabetics

Boston Scientific is emphasizing the performance of its Taxus paclitaxel-eluting stent in diabetic patients as a possible edge over rival Johnson & Johnson's Cypher sirolimus-eluting stent